Piper Sandler analyst Adam Maeder reaffirmed an ‘Overweight’ rating for Edwards Lifesciences (EW) and increased the price target from $98.00 to $100.00. This adjustment reflects continued confidence in the medical device company’s performance. Several other analysts have also raised their price targets for EW, indicating a generally positive outlook and potential for growth, with an average target price of $96.09 among 31 analysts.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Piper Sandler Raises Price Target for Edwards Lifesciences (EW) to $100 | EW Stock News
Piper Sandler analyst Adam Maeder reaffirmed an ‘Overweight’ rating for Edwards Lifesciences (EW) and increased the price target from $98.00 to $100.00. This adjustment reflects continued confidence in the medical device company’s performance. Several other analysts have also raised their price targets for EW, indicating a generally positive outlook and potential for growth, with an average target price of $96.09 among 31 analysts.